Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (61-70 of 140) with videos related to

Pageof 14
Sort By:
Plos One|October 15, 2015
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control StudyDaniel D Murray, Kazuo Suzuki, Matthew Law, et al.
Antiviral Therapy|March 27, 2009
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patientsSarah L Pett, Michael C McCarthy, David A Cooper, et al.
Plos One|March 5, 2013
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control studySonja M Bjerk, Jason V Baker, Sean Emery, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophyDianne L Carey, David Baker, Gary D Rogers, et al.
Plos One|August 30, 2018
Changes in plasma lipidome following initiation of antiretroviral therapyJanine M Trevillyan, Gerard Wong, Rebekah Puls, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2019
ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START TrialIrini Sereti, Roy M Gulick, Sonya Krishnan, et al.
Lancet (London, England)|February 14, 2004
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trialAndrew Carr, Cassy Workman, Dianne Carey, et al.
Human Vaccines|September 25, 2010
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infectionAtchriya Hemachandra, Rebekah L Puls, Sunee Sirivichayakul, et al.
AIDS Research and Human Retroviruses|June 9, 2009
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppressionHelen Byakwaga, John M Murray, Kathy Petoumenos, et al.
Journal of Clinical Microbiology|November 19, 2013
Reply to "Issues on results of the external quality assessment for proviral DNA testing of HIV-1 Tropism in the Maraviroc Switch collaborative study"Elise Tu, Luke C Swenson, Sally Land, et al.
Pageof 14

Showing results (61-70 of 140) with videos related to

Sort By:
Pageof 14
Plos One|October 15, 2015
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control StudyDaniel D Murray, Kazuo Suzuki, Matthew Law, et al.
Antiviral Therapy|March 27, 2009
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patientsSarah L Pett, Michael C McCarthy, David A Cooper, et al.
Plos One|March 5, 2013
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control studySonja M Bjerk, Jason V Baker, Sean Emery, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophyDianne L Carey, David Baker, Gary D Rogers, et al.
Plos One|August 30, 2018
Changes in plasma lipidome following initiation of antiretroviral therapyJanine M Trevillyan, Gerard Wong, Rebekah Puls, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2019
ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START TrialIrini Sereti, Roy M Gulick, Sonya Krishnan, et al.
Lancet (London, England)|February 14, 2004
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trialAndrew Carr, Cassy Workman, Dianne Carey, et al.
Human Vaccines|September 25, 2010
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infectionAtchriya Hemachandra, Rebekah L Puls, Sunee Sirivichayakul, et al.
AIDS Research and Human Retroviruses|June 9, 2009
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppressionHelen Byakwaga, John M Murray, Kathy Petoumenos, et al.
Journal of Clinical Microbiology|November 19, 2013
Reply to "Issues on results of the external quality assessment for proviral DNA testing of HIV-1 Tropism in the Maraviroc Switch collaborative study"Elise Tu, Luke C Swenson, Sally Land, et al.
Pageof 14